Gossamer Bio, Inc. (GOSS)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 1
Do Nothing: fundamentalScore 1 and qualitativeScore 1 are both below the required floor of 3; strategy blocks bullish entries regardless of the oversold but still-bearish chart.
Company overview
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing seralutinib for treating pulmonary hypertension and pulmonary arterial hypertension in the U.S. The company is advancing GB002, an inhaled small molecule inhibitor, currently in Phase 3 trials for PAH. Gossamer Bio has licensing agreements with Pulmokine, Inc. for the development and commercialization of GB002.
Fundamental
very weakGossamer Bio faces severe liquidity and survival risks, with a going-concern warning and negative equity.
Highly speculative clinical-stage biotech with an explicit going-concern warning in the most recent quarterly filing. Liquidity is limited relative to cash burn, profitability and free cash flow are deeply negative, and negative equity plus sub-$1 Nasdaq bid-price noncompliance (reverse split authorized) increase the risk of dilution and unfavorable capital actions. The upside case is event-driven around a targeted seralutinib NDA submission, but near-term financing and regulatory outcomes dominate.
Sentiment
very weakSentiment is dominated by regulatory and financing risks, with low-confidence upside tied to speculative events.
Media tone deteriorated over the last ~14 days after broad coverage tying a major drawdown to negative Phase 3 PROSERA/seralutinib headlines (announced), with last-14d polarity_score around -0.15 vs a near-flat 30–90d baseline (~-0.01). Severe red-flag cap applied due to substantial-doubt going-concern disclosure (and related listing/financing overhang), making near-term price action highly risk-skewed despite pockets of speculative bounce chatter.
Technical
very weakThe stock is in a bearish trend, trading below key moving averages with weak momentum.
Trend is decisively bearish: the 0.14 close sits below SMA20/50/200 (0.17/0.17/1.27), EMA9/21 (0.17/0.17), and daily VWAP 0.15. Momentum is weak with RSI 37.50 and Williams %R -100.00, while the raw MACD remains slightly negative and ADX 30.75 shows the downtrend still has force.
You’re looking at 2026-08-18 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.